Status:
COMPLETED
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Lead Sponsor:
NCIC Clinical Trials Group
Conditions:
Bladder Cancer
Breast Cancer
Eligibility:
All Genders
18-120 years
Phase:
PHASE1
Brief Summary
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of...
Detailed Description
OBJECTIVES: Primary * Determine the dose-limiting toxicity and recommended phase II dose of OGX-011 when administered with docetaxel in patients with metastatic or locally recurrent solid tumors. S...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed solid tumors that have been shown to overexpress clusterin, including but not limited to, any of the following:
- Prostate cancer
- Renal cell carcinoma
- Non-small cell lung cancer
- Bladder cancer
- Breast cancer
- Ovarian cancer
- Metastatic or locally recurrent disease
- Refractory to standard curative therapy or no standard curative therapy exists
- Patients with prostate cancer must be hormone refractory (i.e., have documented evidence of progression while receiving androgen ablative therapy)
- Measurable or nonmeasurable disease
- Measurable disease defined as measurable lesion ≥ 20 mm by x-ray, physical exam, or nonspiral CT scan or ≥ 10 mm by spiral CT scan
- No documented CNS metastases
- Hormone receptor status not specified
- PATIENT CHARACTERISTICS:
- Menopausal status not specified
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- Absolute granulocyte count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin normal
- Creatinine ≤ 2 times upper limit of normal (ULN)
- AST and ALT ≤ 1.5 times ULN
- PT/INR and PTT normal
- No uncontrolled pain
- No known bleeding disorder
- No history of serious allergic reaction to taxane (paclitaxel or docetaxel)
- No preexisting peripheral neuropathy ≥ grade 2
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other serious illness or medical conditions that would preclude study compliance, including any of the following:
- Active uncontrolled infection
- Significant cardiac dysfunction
- No significant neurological disorder that would preclude giving informed consent
- PRIOR CONCURRENT THERAPY:
- No prior strontium chloride Sr 89
- No more than 2 prior chemotherapy regimens, including adjuvant or neoadjuvant chemotherapy (for patients assigned to schedule B \[docetaxel once every 3 weeks\])
- More than 4 weeks since prior chemotherapy and recovered
- At least 4 weeks since prior antiandrogens
- More than 4 weeks since prior external-beam radiotherapy, except low-dose nonmyelosuppressive radiotherapy
- No prior radiotherapy to ≥ 30% of marrow-bearing areas (for patients assigned to schedule B \[docetaxel once every 3 weeks\])
- At least 28 days since prior new anticancer therapy
- At least 28 days since prior and no other concurrent investigational agents
- No concurrent radiotherapy, except low-dose nonmyelosuppressive radiotherapy
- No other concurrent cytotoxic therapy
- Concurrent luteinizing hormone-releasing hormone agonist allowed (if already initiated in patients with prostate cancer)
- No concurrent anticoagulant therapy (i.e., heparin, warfarin)
Exclusion
Key Trial Info
Start Date :
April 4 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 21 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00471432
Start Date
April 4 2003
End Date
December 21 2009
Last Update
August 4 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.